Ultragenyx Pharmaceutical (RARE) Competitors $28.44 +1.12 (+4.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$28.34 -0.11 (-0.37%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. ASND, VRNA, BBIO, BPMC, ROIV, LEGN, RGC, ELAN, RVMD, and GRFSShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Legend Biotech Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols Ultragenyx Pharmaceutical (NASDAQ:RARE) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Which has more volatility & risk, RARE or ASND? Ultragenyx Pharmaceutical has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Which has preferable earnings and valuation, RARE or ASND? Ascendis Pharma A/S has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M4.80-$569.18M-$5.88-4.84Ascendis Pharma A/S$393.54M27.11-$409.12M-$6.28-27.78 Do analysts recommend RARE or ASND? Ultragenyx Pharmaceutical currently has a consensus target price of $83.08, suggesting a potential upside of 192.11%. Ascendis Pharma A/S has a consensus target price of $223.67, suggesting a potential upside of 28.19%. Given Ultragenyx Pharmaceutical's higher possible upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer RARE or ASND? In the previous week, Ultragenyx Pharmaceutical had 11 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 22 mentions for Ultragenyx Pharmaceutical and 11 mentions for Ascendis Pharma A/S. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Ascendis Pharma A/S's score of 0.54 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 7 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RARE or ASND more profitable? Ultragenyx Pharmaceutical has a net margin of -93.04% compared to Ascendis Pharma A/S's net margin of -93.22%. Ascendis Pharma A/S's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-93.04% -186.49% -36.81% Ascendis Pharma A/S -93.22%N/A -33.29% Do institutionals & insiders have more ownership in RARE or ASND? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryUltragenyx Pharmaceutical and Ascendis Pharma A/S tied by winning 8 of the 16 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.58B$3.00B$5.48B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-4.8417.6228.6723.80Price / Sales4.80178.97373.5466.64Price / CashN/A41.9535.4557.96Price / Book10.308.508.275.55Net Income-$569.18M-$55.06M$3.24B$259.03M7 Day Performance4.02%-3.98%-3.69%-4.59%1 Month Performance-27.93%9.59%4.33%4.46%1 Year Performance-43.65%6.72%25.95%18.03% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.4732 of 5 stars$28.44+4.1%$83.08+192.1%-35.6%$2.58B$560.23M-4.841,294Analyst RevisionASNDAscendis Pharma A/S3.079 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.04B$368.70M-26.141,017Analyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1954 of 5 stars$105.09-0.2%$109.00+3.7%+365.2%$8.95B$42.28M-52.5530Positive NewsUpcoming EarningsShort Interest ↑BBIOBridgeBio Pharma4.7123 of 5 stars$46.23-0.2%$61.50+33.0%+80.9%$8.78B$221.90M-13.10400Upcoming EarningsAnalyst ForecastBPMCBlueprint Medicines1.0661 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsROIVRoivant Sciences1.8472 of 5 stars$11.35-1.7%$16.50+45.4%+6.5%$7.72B$29.05M-45.40860Upcoming EarningsLEGNLegend Biotech3.5917 of 5 stars$41.51-4.3%$73.33+76.7%-29.5%$7.63B$627.24M-70.352,609Positive NewsRGCRegencell Bioscience0.0502 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.8056 of 5 stars$14.59-2.2%$16.17+10.8%+5.9%$7.25B$4.44B19.729,000Positive NewsUpcoming EarningsRVMDRevolution Medicines4.467 of 5 stars$37.26-1.7%$68.91+84.9%-19.1%$6.94B$11.58M-9.32250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.1017 of 5 stars$10.09-0.1%$10.30+2.1%+41.1%$6.94B$7.21B8.6223,822Dividend Announcement Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Legend Biotech Alternatives Regencell Bioscience Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Grifols Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts